HK Stock Market Move | ALPHAMAB-B (09966) plunged more than 14% in the morning trading session, and the company was removed from the list of Hong Kong Stock Connect. Previously, it was expected to achieve annual profits for the first time.

ALPHAMAB-B(09966) fell more than 14% in early trading, with a decrease of 12.85% as of the time of writing, trading at 5.29 Hong Kong dollars, with a turnover of 171.259 million Hong Kong dollars. On the news front, on February 21, Hang Seng Index Limited announced the quarterly review results, with ALPHAMAB-B being removed from the Hang Seng Composite Index. On March 10, the Shenzhen Stock Exchange announced that the list of securities under Hong Kong Stock Connect has been adjusted and will be effective from March 10, 2025, with ALPHAMAB-B being removed from the list. It is worth noting that Kangning Jer Pharmaceutical is scheduled to hold a board meeting on March 25 to approve annual performance. The company previously released a profit warning, expecting a profit of not less than 150 million RMB in 2024, compared to a loss of 211 million RMB in 2023, achieving annual profitability for the first time. This is mainly based on three authorized cooperation and sales revenues: in January, June, and September of 2024, Kangning Jer respectively reached commercial cooperation agreements with Glenmark Company, ArriVent BioPharma, and CSPC PHARMA.